CSBR (Champions Oncology) 3-Month Share Buyback Ratio: 0.00% (As of Apr. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSBR Champions Oncology Inc CSBR
57 GF Score
Price $4.91
GF Value $6.68
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Champions Oncology 3-Month Share Buyback Ratio?

Champions Oncology CSBR -0.80% 57 3-Month Share Buyback Ratio is 0.00 as of Apr. 2026. GuruFocus rates CSBR with a GF Score™ of 57/100 and a GF Value™ of $6.68 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Champions Oncology's current 3-Month Share Buyback Ratio was 0.00%.


Champions Oncology  (NAS:CSBR) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Champions Oncology 3-Month Share Buyback Ratio Related Terms


CSBR vs RLYB, NRXS, VRCA: 3-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, Champions Oncology's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology 3-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's 3-Month Share Buyback Ratio falls into.


CSBR
57GF Score
Champions Oncology Inc CSBR
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology 3-Month Share Buyback Ratio Calculation

Champions Oncology's 3-Month Share Buyback Ratio for the quarter that ended in Apr. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Jan. 2026 ) - Shares Outstanding (EOP) (Apr. 2026 )) / Shares Outstanding (EOP) (Jan. 2026 )
=(13.887 - 13.887) / 13.887
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 0.00 mean?
Champions Oncology (CSBR) has a 3-Month Share Buyback Ratio of 0.00 as of Apr. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Champions Oncology and its competitors.
Is Champions Oncology's 3-Month Share Buyback Ratio too high?
Champions Oncology's current 3-Month Share Buyback Ratio is 0.00. Overall, Champions Oncology has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's 3-Month Share Buyback Ratio compare to RLYB and NRXS?
Champions Oncology's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Champions Oncology and its competitors. Champions Oncology's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.68, compared to a current price of $4.91 — trading 26.5% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Champions Oncology's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Champions Oncology (CSBR), the current 3-Month Share Buyback Ratio is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $4.91 is trading 26.5% below its estimated GF Value™ of $6.68. GuruFocus considers Champions Oncology to be Modestly Undervalued.

Key valuation signals for CSBR:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $6.68 vs. price of $4.91 (26.5% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
57GF Score

Get the complete analysis for CSBR

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.91
Price
$6.68
GF Value